Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 5 Aug 2022 |
| Major Shareholder Announcement | 2 Aug 2022 |
| Transactions in connection with share buy-back program | 1 Aug 2022 |
| Transactions in connection with share buy-back program | 25 Jul 2022 |
| Major Shareholder Announcement | 20 Jul 2022 |